ERBB2 and breast cancer: PANACEA was a single-arm, phase 1b-2 proof-of-concept trial that demonstrated that combining trastuzumab with pembrolizumab, had some benefit in 58 patients with trastuzumab-resistant, heavily pretreated, HER2-positive advanced BC.